MX2019007494A - Metodo para modular el crecimiento de celulas madre hematopoyeticas. - Google Patents

Metodo para modular el crecimiento de celulas madre hematopoyeticas.

Info

Publication number
MX2019007494A
MX2019007494A MX2019007494A MX2019007494A MX2019007494A MX 2019007494 A MX2019007494 A MX 2019007494A MX 2019007494 A MX2019007494 A MX 2019007494A MX 2019007494 A MX2019007494 A MX 2019007494A MX 2019007494 A MX2019007494 A MX 2019007494A
Authority
MX
Mexico
Prior art keywords
hsc
stem cell
hematopoietic stem
modulators
cell growth
Prior art date
Application number
MX2019007494A
Other languages
English (en)
Inventor
I Zon Leonard
E North Trista
GOESSLING Wolfran
Original Assignee
Children´S Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children´S Medical Center Corp filed Critical Children´S Medical Center Corp
Publication of MX2019007494A publication Critical patent/MX2019007494A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Materials For Medical Uses (AREA)

Abstract

La presente invención proporciona composiciones y métodos para modular poblaciones de células madre hematopoyéticas al utilizar moduladores de HSC, que son agentes que ya sea que incrementan los números de HSC o disminuyen los números de HSC como sea deseado por una indicación particular. Por ejemplo, los moduladores de HSC encontrados para incrementar los números de HSC incluyen prostaglandina E2 (PGE2) y agentes que estimulan la ruta de PGE2. A la inversa, los moduladores que previenen la síntesis de PGE2 disminuyen los números de HSC. Los moduladores de HSC pueden ser utilizados in vitro, in vivo o ex vivo.
MX2019007494A 2006-03-24 2008-09-23 Metodo para modular el crecimiento de celulas madre hematopoyeticas. MX2019007494A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78596806P 2006-03-24 2006-03-24

Publications (1)

Publication Number Publication Date
MX2019007494A true MX2019007494A (es) 2019-09-06

Family

ID=38526581

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2008012178A MX2008012178A (es) 2006-03-24 2007-03-26 Metodo para modular el crecimiento de celulas madre hematopoyeticas.
MX2019007494A MX2019007494A (es) 2006-03-24 2008-09-23 Metodo para modular el crecimiento de celulas madre hematopoyeticas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2008012178A MX2008012178A (es) 2006-03-24 2007-03-26 Metodo para modular el crecimiento de celulas madre hematopoyeticas.

Country Status (11)

Country Link
US (7) US8168428B2 (es)
EP (3) EP2423303A1 (es)
JP (8) JP5247675B2 (es)
CN (2) CN102626517B (es)
AU (1) AU2007230902B2 (es)
CA (1) CA2647201C (es)
HK (1) HK1173948A1 (es)
MX (2) MX2008012178A (es)
RU (2) RU2493252C2 (es)
WO (1) WO2007112084A2 (es)
ZA (2) ZA200808123B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2647201C (en) 2006-03-24 2016-03-08 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
JP5426389B2 (ja) * 2006-10-20 2014-02-26 チルドレンズ メディカル センター コーポレーション 組織の再生を亢進するための方法
EP2094839B1 (en) 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells
JP5646990B2 (ja) * 2007-04-23 2014-12-24 ストワーズ インスティテュート フォー メディカル リサーチ 幹細胞自己複製のための方法及び組成物
US8871752B2 (en) * 2008-02-19 2014-10-28 Sucampo Ag Method for modulating stem cell growth
ITUD20080058A1 (it) 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
WO2009155041A2 (en) * 2008-05-28 2009-12-23 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
CA3203374A1 (en) 2008-11-06 2010-05-14 Indiana University Research & Technology Corporation Materials and methods to enhance hematopoietic stem cells engraftment procedures
US9056085B2 (en) 2009-02-03 2015-06-16 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010108028A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Compositions comprising cyclic amp enhancers and/or ep ligands, and methods of preparing and using the same
US20120195862A1 (en) * 2009-04-17 2012-08-02 Children's Medical Center Corporation Biomechanical induction of hematopoiesis
EP2251010A1 (en) 2009-05-08 2010-11-17 Sygnis Bioscience GmbH & Co. KG Use of thiabendazole and derivatives thereof for the therapy of neurological conditions
JP6037836B2 (ja) * 2009-11-15 2016-12-07 インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション 特異的プロスタグランジンｅ２受容体の特定を含む幹細胞の送達及び生着を高めるための方法
WO2011062584A1 (en) * 2009-11-19 2011-05-26 Regents Of The University Of Minnesota Reducing inflammation using cell therapy
WO2011143125A2 (en) * 2010-05-10 2011-11-17 Fate Therapeutics, Inc. Biovessels
JP6047489B2 (ja) * 2010-08-12 2016-12-21 フェイト セラピューティクス，インコーポレイテッド 改善された造血幹細胞および前駆細胞療法
SG191908A1 (en) * 2011-01-13 2013-08-30 Scipharm Sarl Method for enhancing engraftment of haematopoetic stem cells
US9592236B2 (en) * 2011-04-28 2017-03-14 Duke University Methods of treating hemoglobinopathies
BR112014007782B1 (pt) 2011-09-30 2021-06-01 Bluebird Bio, Inc. Método para aumentar a eficiência de transdução lentiviral de células progenitoras ou células-tronco hematopoiéticas cd34+, bem como usos terapêuticos de composição compreendendo as ditas células e de pge2, 16,16-dimetil pge2, ou seu análogo
JP6106688B2 (ja) 2011-12-02 2017-04-05 フェイト セラピューティクス，インコーポレイテッド 虚血を処置する改善された方法
AU2012321088B8 (en) 2011-12-02 2016-12-15 Fate Therapeutics, Inc. Enhanced stem cell composition
US9428732B2 (en) 2011-12-05 2016-08-30 Primorigen Biosciences, Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
WO2014081760A1 (en) 2012-11-20 2014-05-30 Duke University Methods of treating hemoglobinopathies
US9943545B2 (en) 2013-03-15 2018-04-17 Fate Therapeutics, Inc. Stem cell culture media and methods of enhancing cell survival
EP2968416A4 (en) 2013-03-15 2016-08-17 Fate Therapeutics Inc BIOLOGICAL ACTIVITY TESTING OF CELLS FOR A THERAPEUTIC POTENTIAL
US9428748B2 (en) * 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
JP2015205835A (ja) * 2014-04-21 2015-11-19 国立大学法人福井大学 中性子線障害防護剤
AU2015249751A1 (en) * 2014-04-23 2016-11-10 Texas Heart Institute Methods of enhancing stem cell engraftment
WO2016014794A1 (en) 2014-07-25 2016-01-28 Sangamo Biosciences, Inc. Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells
CA2960769A1 (en) 2014-09-16 2016-03-24 Sangamo Therapeutics, Inc. Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
CN107429230B (zh) 2015-01-26 2021-11-12 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
JP2018520688A (ja) 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
CN105296427A (zh) * 2015-10-23 2016-02-03 深圳爱生再生医学科技有限公司 造血干细胞的体外扩增培养方法
US20180338899A1 (en) * 2015-10-30 2018-11-29 Norimasa Miura Inhibitors for methylation-related enzymes hat1 and kat8
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN115806940A (zh) 2015-11-04 2023-03-17 菲特治疗公司 多能细胞的基因组工程改造
US11326183B2 (en) 2016-02-12 2022-05-10 Bluebird Bio, Inc. VCN enhancer compositions and methods of using the same
RU2021103425A (ru) 2016-02-12 2021-02-25 Блубёрд Био, Инк. Композиции, повышающие число копий вектора (чкв), и способы их применения
JP2019513010A (ja) * 2016-03-04 2019-05-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー プロスタグランジンｅ２を用いる、筋再生のための組成物および方法
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
EP3541408A4 (en) 2016-11-15 2020-06-24 The Schepens Eye Research Institute, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF ABERRANT ANGIOGENESIS
US20210147796A1 (en) * 2017-06-07 2021-05-20 Academia Sinica Method for removing undifferentiated pluripotent stem cells
WO2018227138A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
US20200362308A1 (en) * 2017-08-22 2020-11-19 The Children's Medical Center Corporation Methods for inducing hematopoietic stem cell specificity
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
AU2018369784B2 (en) 2017-11-14 2023-06-01 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
EP3597211A1 (en) * 2018-07-19 2020-01-22 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Periostin compounds for the treatment of haematological complications
CN109609455A (zh) * 2018-12-28 2019-04-12 诺未科技（北京）有限公司 扩增造血干细胞的培养体系、方法及其用途
US20220127576A1 (en) * 2019-02-13 2022-04-28 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for stem cell therapy
CN110051839A (zh) * 2019-04-16 2019-07-26 诺航生物技术(徐州)有限公司 一种促进脐带血干细胞体外扩增和增强脐带血干细胞移植后造血重建功能的药物
WO2021224633A1 (en) 2020-05-06 2021-11-11 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
US11883436B2 (en) 2020-08-17 2024-01-30 The Board Of Trustees Of The University Of Illinois Method of preparing hematopoietic stem and progenitor cells for transplantation
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA103846A (en) 1906-12-03 1907-02-26 William Bell Manufacture of half-tone printing blocks
US3217903A (en) 1961-01-19 1965-11-16 Mc Graw Edison Co Segregating control
US3753357A (en) 1970-12-14 1973-08-21 Ovitron Res Corp Method and apparatus for the preservation of cells and tissues
US4199022A (en) 1978-12-08 1980-04-22 The United States Of America As Represented By The Department Of Energy Method of freezing living cells and tissues with improved subsequent survival
US4239679A (en) 1979-06-27 1980-12-16 Diamond Shamrock Corporation High bulk density rigid poly(vinyl chloride) resin powder composition and preparation thereof
HU181154B (en) 1980-07-18 1983-06-28 Epitestudomanyi Intezet Shaped building unit and space limiting or dividing structure made of same as well as method for producing the shaped building unit
US4559298A (en) 1982-11-23 1985-12-17 American National Red Cross Cryopreservation of biological materials in a non-frozen or vitreous state
US5004681B1 (en) 1987-11-12 2000-04-11 Biocyte Corp Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood
ATE403713T1 (de) * 1989-10-16 2008-08-15 Amgen Inc Stamzellfaktor
US5114672A (en) 1990-08-27 1992-05-19 Cryo-Cell International, Inc. Method for preserving blood fluid
SG52619A1 (en) * 1993-08-23 1998-09-28 Baxter Int In vitro growth of neutrophil and megakaryocte precursors in serum-free media
AU6125396A (en) * 1995-06-07 1996-12-30 Novartis Ag Serum-free media for primitive hematopoietic cells and metho ds of use thereof
US6372796B1 (en) 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
GB9904281D0 (en) 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
RU2259830C2 (ru) 1999-11-24 2005-09-10 Оно Фармасьютикал Ко., Лтд. Фармацевтическая композиция для лечения заболеваний, связанных с потерей костной массы
TWI247606B (en) 1999-11-24 2006-01-21 Ono Pharmaceutical Co Treating agent for osteopenic diseases
US6226997B1 (en) 1999-12-07 2001-05-08 Cryo-Cell International, Inc. Method and device for maintaining temperature integrity of cryogenically preserved biological samples
US6852534B2 (en) 2000-11-03 2005-02-08 Kourion Therapeutics Gmbh Method to determine an engrafting cell dose of hematopoietic stem cell transplant units
JP4077158B2 (ja) 2001-01-10 2008-04-16 株式会社メニコン 植物性繊維分解剤およびそれを用いた植物性廃棄物の処理法
NZ527849A (en) 2001-02-14 2006-09-29 Anthrogenesis Corp Post-partum mammalian placenta, its use and placental stem cells therefrom
FR2825261B1 (fr) 2001-06-01 2003-09-12 Maco Pharma Sa Ligne de prelevement du sang placentaire comprenant une poche de rincage
US7179643B2 (en) 2001-06-14 2007-02-20 Reliance Life Sciences Pvt. Ltd. Device and a process for expansion of haemopoeitic stem cells for therapeutic use
US8021876B2 (en) 2001-11-15 2011-09-20 Children's Medical Center Corporation Methods of isolation, expansion and differentiation of fetal stem cells from chorionic villus, amniotic fluid, and placenta and therapeutic uses thereof
ATE464373T1 (de) * 2001-12-21 2010-04-15 Mount Sinai Hospital Corp Zelluläre zusammensetzungen und verfahren zur deren bereitung und verwendung
RU2205627C1 (ru) * 2002-05-30 2003-06-10 Открытое акционерное общество "Косметическое объединение "Свобода" Крем для лица, выводящий токсины
EP1563846B1 (en) 2002-10-10 2012-08-29 Ono Pharmaceutical Co., Ltd. Endogenous repair factor production promoters
PL378748A1 (pl) 2003-03-04 2006-05-15 Pfizer Products Inc. Zastosowanie selektywnych agonistów receptora EP2 w leczeniu
US20050054103A1 (en) * 2003-03-07 2005-03-10 Tony Peled Expansion of renewable stem cell populations using modulators of PI 3-kinase
EP1613742A2 (en) 2003-04-08 2006-01-11 YEDA RESEARCH AND DEVELOPMENT Co. LTD. Stem cells having increased sensitivity to a chemoattractant and methods of generating and using same
GB0324523D0 (en) 2003-10-21 2003-11-26 Medical Res Council Compositions and methods of treatment
US8309608B2 (en) 2003-11-06 2012-11-13 Sanofi-Aventis Deutschland Gmbh Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases
IL158868A0 (en) 2003-11-13 2004-05-12 Yeda Res & Dev Methods of generating and using stem cells enriched with immature primitive progenitor
US20080299095A1 (en) * 2004-07-09 2008-12-04 Bc Cancer Agency Nup98-Hox Fusions for Expansion of Hemopoietic Stem Cells
US7147626B2 (en) 2004-09-23 2006-12-12 Celgene Corporation Cord blood and placenta collection kit
WO2006078886A2 (en) 2005-01-18 2006-07-27 Irm Llc Compounds and compositions as wnt signaling pathway modulators
CA2597757C (en) 2005-02-10 2016-06-28 Regents Of The University Of Minnesota Vascular/lymphatic endothelial cells
WO2007117262A2 (en) 2005-07-29 2007-10-18 Athersys, Inc. Culture of non-embryonic cells at high cell density
JP4562618B2 (ja) 2005-08-18 2010-10-13 陽一 佐藤 空き缶処理車
GB2447191B (en) * 2005-12-22 2011-08-03 Es Cell Int Pte Ltd Direct differentiation of cardiomyocytes from human embryonic stem cells
CA2647201C (en) 2006-03-24 2016-03-08 Children's Medical Center Corporation Method to modulate hematopoietic stem cell growth
WO2007148332A1 (en) 2006-06-22 2007-12-27 Yeda Resaerch And Development Co. Ltd Catecholamine receptor modulation
WO2008021475A2 (en) 2006-08-16 2008-02-21 The General Hospital Corporation Compositions and methods for hematopoietic stem cell expansion or for modulating angiogenesis
KR20080042761A (ko) 2006-11-10 2008-05-15 문찬일 렙틴을 이용한 줄기세포 증식방법
EP2094839B1 (en) * 2006-12-08 2020-02-05 University of Rochester Expansion of hematopoietic stem cells

Also Published As

Publication number Publication date
US9028811B2 (en) 2015-05-12
AU2007230902A1 (en) 2007-10-04
JP5247675B2 (ja) 2013-07-24
RU2493252C2 (ru) 2013-09-20
RU2008142106A (ru) 2010-04-27
JP2023112027A (ja) 2023-08-10
US20120189594A1 (en) 2012-07-26
US20120189592A1 (en) 2012-07-26
US20130209424A1 (en) 2013-08-15
US8551782B2 (en) 2013-10-08
EP1999255A2 (en) 2008-12-10
WO2007112084A8 (en) 2008-11-20
ZA200906574B (en) 2010-06-30
RU2425876C2 (ru) 2011-08-10
WO2007112084A9 (en) 2007-11-22
JP2016210802A (ja) 2016-12-15
JP2015232010A (ja) 2015-12-24
JP2009530408A (ja) 2009-08-27
CN102626517B (zh) 2015-07-29
US8563310B2 (en) 2013-10-22
WO2007112084A2 (en) 2007-10-04
ZA200808123B (en) 2010-03-31
US20090285786A1 (en) 2009-11-19
EP3424507A1 (en) 2019-01-09
CN102626517A (zh) 2012-08-08
JP6208719B2 (ja) 2017-10-04
JP6041711B2 (ja) 2016-12-14
JP2022025091A (ja) 2022-02-09
MX2008012178A (es) 2009-01-23
CN101495623B (zh) 2013-09-11
US8168428B2 (en) 2012-05-01
CA2647201C (en) 2016-03-08
CA2647201A1 (en) 2007-10-04
US20130216507A1 (en) 2013-08-22
JP2013155175A (ja) 2013-08-15
JP2019214620A (ja) 2019-12-19
HK1173948A1 (en) 2013-05-31
WO2007112084A3 (en) 2009-01-08
RU2011115827A (ru) 2012-10-27
AU2007230902A8 (en) 2009-07-23
JP6797222B2 (ja) 2020-12-09
US10278990B2 (en) 2019-05-07
US20120189593A1 (en) 2012-07-26
US20130209423A1 (en) 2013-08-15
EP2423303A1 (en) 2012-02-29
US10272110B2 (en) 2019-04-30
JP6530732B2 (ja) 2019-06-12
AU2007230902B2 (en) 2013-03-14
CN101495623A (zh) 2009-07-29
JP2019094347A (ja) 2019-06-20

Similar Documents

Publication Publication Date Title
MX2019007494A (es) Metodo para modular el crecimiento de celulas madre hematopoyeticas.
GEP20146053B (en) Compounds expanding hematopoietic stem cells
UA103623C2 (ru) Регулятор роста растений
MX2009008019A (es) Uso de nanoparticulas carotenoides dispersibles en agua como moduladores de sabor, moduladores de sabor que contiene nanoparticulas carotenoides dispersibles en agua y metodo para modulacion de sabor.
MX2009013706A (es) Celulas multipotentes/pluripotentes y metodos relacionados.
MX2009004164A (es) Metodo para aumentar la regeneracion de tejido.
MY157445A (en) Compounds that modulate intracellular calcium.
SG148171A1 (en) Methods of proliferating stem cells
IN2012DN02984A (es)
MX2009007266A (es) Formulaciones estables de acido s-(+)-abscisico liquidas y de granulo soluble.
MX345116B (es) Modulacion de bcl11a para tratamiento de hemoglobinopatias.
MX2010002712A (es) Compuestos que modulan calcio intracelular.
TNSN08024A1 (en) 7-substituted aza-indazoles, compositions containing same, production method and use thereof
ECSP088854A (es) Moduladores bencimidazolicos de vr1
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
TW200734462A (en) Regulating stem cells
WO2007143689A8 (en) Compositions and methods for modulating vascular development
WO2010129294A3 (en) Small molecules supporting pluripotent cell growth and methods thereof
TW200628428A (en) High calcium fertilizer composition
CR20130184A (es) Composiciones bioactivas de chromobacterium y metabolitos
MX2009005462A (es) Analogos de 7,8-saturados-4,5-epoxi-morfinano.
WO2010048358A3 (en) Ethoxyphenylmethyl inhibitors of sglt2
WO2009135905A3 (en) Mesenchymal stem cells and bone-forming cells
TW200942614A (en) Composition for modulating stem cell growth
MY155410A (en) Compositions and devices